Lantheus Holdings, Inc.: Prostatic Neoplasms trials
The registry lists 22 Prostatic Neoplasms studies with Lantheus Holdings, Inc. as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 1 10Phase 2 7Phase 3 4Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])RecruitingNCT07831824Phase 2/3
- I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).CompletedNCT03939689Phase 2Results posted
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3Results posted
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerCompletedNCT02981368Phase 2/3Results posted
- An Open-label Extension Study of PSMA ADC 2301 in mCRPCCompletedNCT02020135Phase 2Results posted
- A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)CompletedNCT01695044Phase 2Results posted
- A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to HistopathologyCompletedNCT01667536Phase 2Results posted
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate CancerActive, not recruitingNCT06074510Phase 4
- Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Temporarily not availableNCT06033001
- An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate CancerActive, not recruitingNCT05712473
- Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate CancerCompletedNCT02615067Phase 3
- PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerTerminatedNCT02483884Phase 1/2
- 99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404CompletedNCT01654874Phase 1
- A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate CancerCompletedNCT01615406Phase 1
- Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node DissectionCompletedNCT01572701Phase 1
- Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414296Phase 1
- Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate CancerCompletedNCT01414283Phase 1
- PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy VolunteersCompletedNCT01287845Phase 1
- A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing ProstatectomyWithdrawnNCT01279785
- PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy VolunteersCompletedNCT01205321Phase 1
- A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate CancerCompletedNCT00992745Phase 1
- Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging AgentsCompletedNCT00712829Phase 1